After Acadia reported that pimavanserin failed to show a significant benefit in schizophrenia patients on the Positive and Negative Syndrome Scale, or PANSS, Stifel analyst Paul Matteis said he was unsurprised and expects the investment debate to turn towards the implications for the company's investigation of the drug for use in treating schizophrenia negative symptoms and dementia-related psychosis, or DRP. Read-throughs are "debatable," said Matteis, who thinks comparison to DRP is "apples-to-oranges," mostly because of trial designs. The analyst, who still believes Acadia shares trade at a substantial premium to the value of Parkinson's Disease Psychosis alone, has a Hold rating on the stock.